comparemela.com
Home
Live Updates
FDA Grants Fast Track Status to Aglatimagene Besadenovec Plus Valacyclovir for Pancreatic Cancer : comparemela.com
FDA Grants Fast Track Status to Aglatimagene Besadenovec Plus Valacyclovir for Pancreatic Cancer
The FDA has granted fast track designation to aglatimagene besadenovec plus valacyclovir for use as a potential therapeutic option in patients with pancreatic ductal adenocarcinoma.
Related Keywords
,
Candel Therapeutics Inc ,
Candel Therapeutics ,
Peter Tak ,
Fast Track Designation To Aglatimagene Besadenovec Plus Valacyclovir ,
Patients With Pancreatic Ductal Adenocarcinoma ,
Nct02446093 ,
Paul Peter Tak ,
D ,
Phd ,
Medsci ,
comparemela.com © 2020. All Rights Reserved.